Results 351 to 360 of about 1,467,646 (404)

First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors. [PDF]

Br J Cancer
Day D, Ganju V, Chung K, Si L, Mao L, Aghmesheh M, Hoyer R, Brewin K, Zeng S, Zhang M, Lu Q, Jiang C, Ren F, Zhu Y, Guo J.   +14 more
europepmc   +1 more source

Severe dual fungal infection after bispecific antibody therapy: A case of invasive aspergillosis and mucormycosis in immunocompromised patient. [PDF]

IDCases
Sakalihasan S, Lifrange F, Czajkowski M, Goncette V, Duysinx B, Lovinfosse P, Can D, Schils R, Hayette MP, De Voeght A.   +9 more
europepmc   +1 more source

Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy. [PDF]

Mater Today Bio
Xue F, Ren X, Kong C, Wang J, Liu L, Hu J, Shen N, Tang Z.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Bispecific Antibodies for the Treatment of Neuroblastoma

SSRN Electronic Journal, 2022
Bispecific antibodies (BsAb) are a new generation of antibody-based therapy, conveying artificial specificity to polyclonal T cells or radiohaptens. These drugs have been successfully implemented to cure hematologic malignancies and are under clinical investigation for solid tumors including HRNB.
Madelyn, Espinosa-Cotton, Nai-Kong V, Cheung   +1 more
openaire   +2 more sources

CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models

Science Translational Medicine, 2022
Although many patients with diffuse large B cell lymphoma (DLBCL) may achieve a complete response to frontline chemoimmunotherapy, patients with relapsed/refractory disease typically have poor outcomes.
Joyce Wei, Welby Montalvo-Ortiz, Lola Yu, Amanda Krasco, Kara Olson, Sahar Rizvi, N. Fiaschi, Sandra Coetzee, Fang Wang, Erica Ullman, H. Ahmed, E. Herlihy, Ken Lee, L. Havel, Terra Potocky, S. Ebstein, D. Frleta, A. Khatri, Stephen Godin, S. Hamon, Jurriaan Brouwer-Visser, T. Gorenc, D. MacDonald, Aynur Hermann, A. Chaudhry, A. Sirulnik, W. Olson, John Lin, G. Thurston, I. Lowy, A. Murphy, Eric J. Smith, V. Janković, M. Sleeman, D. Skokos   +34 more
semanticscholar   +1 more source

Bispecific Antibodies in Lymphoma

International Reviews of Immunology, 1993
Journal Article ; Review ; SCOPUS: ar.j ; info:eu-repo/semantics ...
Brissinck, J, Demanet, Christian, Moser, Muriel, Leo, Oberdan, Thielemans, Kris   +4 more
openaire   +3 more sources

Engineering bispecific antibodies

Current Opinion in Biotechnology, 1993
Bispecific antibodies have immense potential as reagents and in medicine. Until recently, they were made by combining monoclonal antibodies of two different specificities in vitro, or by fusion of the corresponding hybridomas. Protein engineering now offers the chance to construct a range of small 'designer' bispecific antibodies using antibody ...
Philipp Holliger, Greg Winter
openaire   +3 more sources

Production of Bispecific Antibodies

Current Protocols in Immunology, 1995
AbstractBispecific antibodies (bsAbs) contain two different binding specificities within a single molecule and can specifically bind two different molecules together. BsAbs can be produced by chemically cross‐linking purified antibodies or Fab fragments with reducible disulfide bonds or nonreducible thioether bonds, both of which are described in this ...
Bert J.E.G. Bast, David M. Segal
openaire   +3 more sources